Evidence map›Paper›PMID 40178895›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2025

RPE-specific MCT2 expression promotes cone survival in models of retinitis pigmentosa.

Laurel C Chandler, Apolonia Gardner, Constance L Cepko

Abstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. AAV NRF2 gene therapy preserves retinal structure and function in rodent models of oxidative damage.Molecular therapy : the journal of the American Society of Gene Therapy · 2026
    Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Laurel C ChandlerDepartment of Genetics, Blavatnik Institute, Harvard Medical School, Boston, MA 02115.ORCID 0000-0001-9651-1929
Apolonia GardnerDepartment of Genetics, Blavatnik Institute, Harvard Medical School, Boston, MA 02115.
Constance L CepkoDepartment of Genetics, Blavatnik Institute, Harvard Medical School, Boston, MA 02115.ORCID 0000-0002-9945-6387

Funding

Elucidating Host Responses to AAV Ocular Gene Therapy VectorsF31EY035867 · NEI · HARVARD MEDICAL SCHOOL · PI GARDNER, APOLONIA · 2024 to 2025
$81k
HHS | National Institutes of Health (NIH) 1F31EY035867-01Howard Hughes Medical Institute (HHMI) N/ANEI NIH HHS F31 EY035867Roche Holding | Spark Therapeutics (Spark Therapeutics, Inc.) A48978
6 · The paper itself

Abstract

Retinitis pigmentosa (RP) is the most common cause of inherited retinal degeneration worldwide. It is characterized by the sequential death of rod and cone photoreceptors, the cells responsible for night and daylight vision, respectively. Although the expression of most RP genes occurs only in rods, there is a secondary degeneration of cones. One possible mechanism of cone death is metabolic dysregulation. Photoreceptors are highly metabolically active, consuming large quantities of glucose and producing substantial amounts of lactate. The retinal pigment epithelium (RPE) mediates the transport of glucose from the blood to photoreceptors and, in turn, removes lactate, which can influence the rate of consumption of glucose by the RPE. One model for metabolic dysregulation in RP suggests that following the death of rods, lactate levels are substantially diminished causing the RPE to withhold glucose, resulting in nutrient deprivation for cones. Here, we present adeno-associated viral vector-mediated delivery of monocarboxylate transporter 2 (MCT2,

Indexed as

Monocarboxylic Acid TransportersRetinal Cone Photoreceptor CellsRetinal Pigment EpitheliumRetinitis PigmentosaAnimalsDisease Models, AnimalGlucoseHumansLactic AcidMiceGlucoseLactic AcidMonocarboxylic Acid Transportersgene therapymetabolismretinal pigment epitheliumretinitis pigmentosa

Identifiers

PMID40178895
PMCPMC12002273

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.